-
公开(公告)号：US20230129652A1
公开(公告)日：2023-04-27
申请号：US17883302
申请日：2022-08-08
Applicant: Avedro, Inc.
Inventor： Marc D. Friedman , Alexandra Nicklin , Pavel Kamaev
Abstract: Example eye treatments detennine an area at a surface of a cornea for delivery of a cross-linking agent. The example treatments disrupt tissue at the area at the surface of the con1ea up to a depth corresponding to apical layers of superficial squamous cells of the cornea, e.g., no greater than approximately 10 μm to approximately 15 lm. The example treatments apply a cross-linking agent to the area at the surface of the cornea. The cross-linking agent is transmitted through the disrupted area at a greater rate relative to non disrupted areas of the cornea. The example treatments deliver photoactivating light to the cornea. The photoactivating light activates the cross-linking agent to generate cross-linking activity in the cornea.
-
公开(公告)号：US20180236077A1
公开(公告)日：2018-08-23
申请号：US15901496
申请日：2018-02-21
Applicant: Avedro, Inc.
Inventor： Marc D. Friedman , Pavel Kamaev , Martin Joseph Coffee , Rajesh K. Rajpal , Alexandra Nicklin
CPC classification number: A61K41/0057 , A61F9/0079 , A61K9/0048 , A61K47/186 , A61N5/062 , A61N2005/0661 , A61P27/02
Abstract: Formulations, are used for eye treatments, e.g., cross-linking treatments. For example, a therapeutic formulation includes a photosensitizer and delivery agent(s), wherein the delivery agent(s) include at least one of: anesthetic agent(s), analgesic agent(s), tonicity agent(s), or shear-thinning, or viscosity-increasing agent(s). In another example, a method includes applying preparatory formulation(s) to increase a permeability of a corneal epithelium, and applying therapeutic formulation(s) to the epithelium, where the preparatory formulation(s) include zinc metalloproteinase, copper metalloproteinase, papain, bromelain, actinidin, ficain, N-acetylcysteine, ambroxol, carbocisteine, and/or erdosteine. In yet another example, a method includes applying therapeutic formulation(s) to a corneal epithelium to deliver the therapeutic formulation(s) to a stroma, and applying enhancement formulation(s) to the epithelium in response to applying the therapeutic formulation(s), where: the enhancement formulation(s) remove the therapeutic formulation(s) from the epithelium; close tight junctions of the epithelium; promote oxidation for the therapeutic agent(s); and/or further deliver the therapeutic formulation(s) to the stroma.
-
Patent Agency Ranking
公开(公告)号：US11406805B2
公开(公告)日：2022-08-09
申请号：US16324489
申请日：2017-08-08
Applicant: Avedro, Inc.
Inventor： Marc D. Friedman , Alexandra Nicklin , Pavel Kamaev
Abstract: Example eye treatments determine an area at a surface of a cornea for delivery of a cross-linking agent. The example treatments disrupt tissue at the area at the surface of the cornea up to a depth corresponding to apical layers of superficial squamous cells of the cornea, e.g., no greater than approximately 10 μm to approximately 15 μm. The example treatments apply a cross-linking agent to the area at the surface of the cornea. The cross-linking agent is transmitted through the disrupted area at a greater rate relative to non disrupted areas of the cornea. The example treatments deliver photoactivating light to the cornea. The photoactivating light activates the cross-linking agent to generate cross-linking activity in the cornea.
-
公开(公告)号：US10342697B2
公开(公告)日：2019-07-09
申请号：US15486778
申请日：2017-04-13
Applicant: Avedro, Inc.
Inventor： Marc D. Friedman , Pavel Kamaev , Stephen Zolla , Alexandra Nicklin
IPC: A61F9/00 , A61K31/525 , A61N5/06
Abstract: A drug delivery device includes a drug-eluting element defined by a plurality of outer surfaces including a delivery surface and one or more other non-delivery surfaces. The delivery surface is positioned against tissue of an eye and shaped to define an area of targeted tissue to receive a drug. The drug-eluting element holds the drug when the delivery surface is not positioned against the tissue. Responsive to the delivery surface being positioned against the tissue, the drug-eluting element releases the drug to the area of targeted tissue through the delivery surface. The drug delivery device includes one or more barrier structures disposed along the one or more non-delivery surfaces of the drug-eluting element. The one or more barrier structures substantially inhibit release of the drug from the drug-eluting element through the one or more non-delivery surfaces.
-
公开(公告)号：US20200345847A1
公开(公告)日：2020-11-05
申请号：US16933059
申请日：2020-07-20
Applicant: Avedro, Inc.
Inventor： Marc D. Friedman , Pavel Kamaev , Martin Joseph Coffee , Rajesh K. Rajpal , Alexandra Nicklin
Abstract: Formulations, are used for eye treatments, e.g., cross-linking treatments. For example, a therapeutic formulation includes a photosensitizer and delivery agent(s), wherein the delivery agent(s) include at least one of: anesthetic agent(s), analgesic agent(s), tonicity agent(s), or shear-thinning, or viscosity-increasing agent(s). In another example, a method includes applying preparatory formulation(s) to increase a permeability of a corneal epithelium, and applying therapeutic formulation(s) to the epithelium, where the preparatory formulation(s) include zinc metalloproteinase, copper metalloproteinase, papain, bromelain, actinidin, ficain, N-acetylcysteine, ambroxol, carbocisteine, and/or erdosteine. In yet another example, a method includes applying therapeutic formulation(s) to a corneal epithelium to deliver the therapeutic formulation(s) to a stroma, and applying enhancement formulation(s) to the epithelium in response to applying the therapeutic formulation(s), where: the enhancement formulation(s) remove the therapeutic formulation(s) from the epithelium; close tight junctions of the epithelium; promote oxidation for the therapeutic agent(s); and/or further deliver the therapeutic formulation(s) to the stroma.
-
公开(公告)号：US20190192840A1
公开(公告)日：2019-06-27
申请号：US16324489
申请日：2017-08-08
Applicant: Avedro, Inc.
Inventor： Marc D. Friedman , Alexandra Nicklin , Pavel Kamaev
CPC classification number: A61M37/00 , A61F9/0017 , A61F9/007 , A61F9/008 , A61F9/00802 , A61F9/00804 , A61F2009/00844 , A61F2009/00872 , A61F2009/00893 , A61F2009/00895 , A61M2037/0007 , A61M2037/0046 , A61M2205/051 , A61M2210/0612 , A61N5/062
Abstract: Example eye treatments determine an area at a surface of a cornea for delivery of a cross-linking agent. The example treatments disrupt tissue at the area at the surface of the cornea up to a depth corresponding to apical layers of superficial squamous cells of the cornea, e.g., no greater than approximately 10 μm to approximately 15 μm. The example treatments apply a cross-linking agent to the area at the surface of the cornea. The cross-linking agent is transmitted through the disrupted area at a greater rate relative to non disrupted areas of the cornea. The example treatments deliver photoactivating light to the cornea. The photoactivating light activates the cross-linking agent to generate cross-linking activity in the cornea.
-
公开(公告)号：US20170296383A1
公开(公告)日：2017-10-19
申请号：US15486778
申请日：2017-04-13
Applicant: Avedro, Inc.
Inventor： Marc D. Friedman , Pavel Kamaev , Stephen Zolla , Alexandra Nicklin
IPC: A61F9/00 , A61N5/06 , A61K31/525
CPC classification number: A61F9/0008 , A61F9/0017 , A61K31/525 , A61N5/062
Abstract: A drug delivery device includes a drug-eluting element defined by a plurality of outer surfaces including a delivery surface and one or more other non-delivery surfaces. The delivery surface is positioned against tissue of an eye and shaped to define an area of targeted tissue to receive a drug. The drug-eluting element holds the drug when the delivery surface is not positioned against the tissue. Responsive to the delivery surface being positioned against the tissue, the drug-eluting element releases the drug to the area of targeted tissue through the delivery surface. The drug delivery device includes one or more barrier structures disposed along the one or more non-delivery surfaces of the drug-eluting element. The one or more barrier structures substantially inhibit release of the drug from the drug-eluting element through the one or more non-delivery surfaces.
-
-
-
-
-
-
Search Results
7
records
(took 0.013 seconds)
